The life sciences industry is currently witnessing a high-stakes technological transformation, as two industry titans—Salesforce and Veeva Systems—engage in an aggressive battle to define the "agentic" future of pharmaceutical commercialization, clinical trials, and patient engagement.
As Veeva Systems CEO Peter Gassner addressed stakeholders at the annual Veeva Commercial Summit in Boston, Salesforce seized the moment to announce that its Agentforce Life Sciences platform has secured over 140 enterprise clients. The roster includes pharmaceutical heavyweights such as Novartis, AstraZeneca, Moderna, and Merck Animal Health, signaling a major shift in how the industry adopts artificial intelligence.
At the heart of this competition is a fundamental disagreement over architecture: Salesforce is championing a "headless" AI model that prioritizes interoperability and external ecosystem integration, while Veeva is doubling down on a vertically integrated, "depth-inside-the-app" approach designed to keep data and workflows within its proprietary ecosystem.
Main Facts: The Battle for the Agentic Enterprise
The shift toward "agentic" AI represents a transition from simple chatbots to autonomous digital workers capable of performing complex, multi-step tasks. In the life sciences sector, where regulatory compliance is paramount, these agents are being tasked with managing HCP (healthcare professional) interactions, clinical trial documentation, and patient support programs.
Salesforce’s Agentforce platform is being marketed as a broad, AI-native suite designed to function across the entire spectrum of pharmaceutical operations. Joe Ferraro, SVP and GM of life sciences at Salesforce, emphasized that the 140-client milestone reflects broad adoption across clinical, medical, and commercial functions.
Conversely, Veeva’s strategy centers on its new Falcon platform. Announced on May 27, 2026, Falcon is designed to bring agentic labor specifically to the drug development lifecycle, covering clinical, regulatory, and safety domains. While Salesforce positions itself as a universal AI layer, Veeva aims to be the specialized "operating system" for the life sciences industry, ensuring that every AI action is anchored in industry-specific compliance standards.
A Chronological Perspective: From CRM to Autonomous Agents
The current race is the culmination of over a decade of investment in machine learning and predictive analytics.
- 2014: Salesforce CEO Marc Benioff declared Salesforce an "AI-first company" during an internal all-hands meeting, marked by the acquisition of RelateIQ for $390 million.
- 2016: Salesforce introduced Einstein, the first AI designed specifically for CRM, setting the stage for deep predictive capabilities.
- 2024 (September): Salesforce officially launched the Agentforce platform at Dreamforce, branding it "digital labor" and setting an ambitious goal of empowering one billion agents by the end of 2025.
- 2025 (December): Veeva launched its Vault CRM Free Text, Voice, and Pre-call agents, marking its first major foray into generative AI for field teams.
- 2026 (March): Veeva acquired Ostro, an AI brand-engagement platform, for approximately $100 million to bolster its conversational AI capabilities using MLR-approved content.
- 2026 (May): Salesforce reported that it had processed 28.6 trillion AI tokens, a 152% increase quarter-over-quarter, with Agentforce generating $1.2 billion in annual recurring revenue.
- 2026 (May/June): Veeva officially unveiled its Falcon platform and confirmed an August 2026 release for its "Vault AI Tab," a conversational interface for existing Vault data.
Supporting Data: By the Numbers
The scale of investment from both companies highlights the massive potential market for autonomous business processes. Salesforce, with its vast engineering resources, is leveraging its massive cloud footprint to scale faster than many industry-specific rivals.
Ferraro noted that Salesforce now employs thousands of engineers dedicated exclusively to AI. This scale, he argues, allows Salesforce to move faster than Veeva. The company’s financial performance supports this: Agentforce has become one of the fastest-growing segments for the software giant, with its $1.2 billion ARR milestone achieved in a remarkably short period.
For Veeva, the data advantage is qualitative rather than quantitative. By focusing on "depth-inside-the-app," Veeva ensures that its agents are constrained by the existing security and permissions frameworks inherent in its Vault platform. Its acquisition of Ostro demonstrates a strategic pivot toward using AI as a bridge between approved content and real-time patient/HCP inquiries, mitigating the risks of "hallucination" by strictly limiting the model to verified data.
Official Responses: The "Headless" vs. "Integrated" Debate
The most significant divergence between the two firms lies in their philosophy regarding where the AI lives.
The Salesforce "Headless" Pitch
Salesforce is pushing the "headless" concept, which effectively "pops the top" off their platform. By exposing APIs, data models, and workflows as Model Context Protocol (MCP) tools, Salesforce allows its platform to integrate into external AI interfaces—like Anthropic’s Claude—while maintaining Salesforce’s underlying security and compliance.
"I was with a customer yesterday who has made a significant investment in Anthropic, and they are going to use our MCP service for Agentforce Life Sciences to bring all of those compliant workflows directly inside Claude," said Ferraro. This strategy positions Salesforce not just as a destination, but as the underlying infrastructure layer for the entire enterprise AI ecosystem.
The Veeva "Depth" Strategy
Veeva remains committed to the "walled garden" approach. Their agents are built to exist within the Veeva environment, working in-context against their specific documents and workflows. This is a deliberate design choice aimed at life sciences firms that demand high-assurance systems where the AI cannot operate "off-script."
Veeva fixes the model layer for its standard agents, utilizing Anthropic and Amazon models hosted on Amazon Bedrock. By limiting the model’s exposure to the outside world, Veeva aims to provide a more predictable, risk-averse experience that is easier to validate for regulatory bodies like the FDA.
Implications for the Life Sciences Industry
The transition to agentic AI is not merely about productivity; it is about the fundamental restructuring of how pharmaceutical companies operate.
1. Accelerated Onboarding and Reduced Consulting Dependency
Salesforce reports that smaller life science customers are onboarding in as little as one month. Part of this speed is attributed to "agent-led configuration." Forward-deployed engineers can now use tools like Claude Code to automate the setup of complex interfaces, replacing the manual, screen-by-screen configuration that previously required armies of consultants.
2. The Determinism Challenge
In a regulated industry, the probabilistic nature of Large Language Models (LLMs) is a liability. Both companies are addressing this through deterministic "guardrails." Salesforce uses "Agent Script" to force the AI to adhere to approved templates and consent statuses. Veeva relies on the "Vault AI Tab" and in-context document processing to ensure that AI responses are strictly confined to the scope of approved, verified content.
3. The Future of Work for Field Teams
The "Agentic Commercial Model" changes the nature of the rep-HCP relationship. Instead of spending hours preparing for meetings or navigating internal CRM screens, field teams can rely on AI to summarize declining prescriber trends, suggest the next-best action, and draft compliant communications.
4. A Divided Market
The industry will likely see a bifurcation in preference. Global conglomerates with large, heterogeneous tech stacks may lean toward the "headless" flexibility of Salesforce to unify data across disparate departments. Meanwhile, "Veeva-centric" organizations—those that have already built their entire clinical and commercial workflow within the Vault ecosystem—will likely find the "depth-inside-the-app" model of Falcon to be a more natural, compliant extension of their existing operations.
As the industry moves toward 2027, the success of these platforms will be measured not just by the number of clients signed, but by their ability to prove that agentic labor can satisfy stringent regulatory requirements while delivering the promised productivity gains. The competition is fierce, the stakes are high, and for the life sciences sector, the "AI-first" era has officially arrived.
About the Author
